key: cord-1012694-aps9iuoy
authors: Desai, Anuja; Desai, Parth; Mehta, Jigar; Sachora, Wasimahmed; Bharti, Neeraj; Patel, Tushar; Sukhwani, Kalpesh; Jain, Ankita; Sorathiya, Dipesh; Nanda, Vivek; Mehta, Parin; Desai, Adit
title: “Measuring the Impact of single dose of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre”
date: 2021-10-21
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.032
sha: b00d140989d722f9ea0c559cb63d0beea4d811f1
doc_id: 1012694
cord_uid: aps9iuoy

Objective: To comparatively evaluate ICU requirement, length of stay and mortality between single dose vaccinated and non-vaccinated hospitalized COVID-19 patients. Design: Retrospective, observational study from 1st April 2021 till 30th June 2021 carried out in a tertiary care hospital in Western Indian region. Results: Of the 569 patients enrolled in the study based on the eligibility criteria, 137 (24.08%) patients had received a single dose of ChAdOx1 nCoV-19 vaccine while 432 (75.92%) patients had not received any form of vaccination. Overall length of stay in the hospital was similar for both groups however a significant difference was seen in length of stay in ward and ICU. Vaccinated patients were admitted for 6.21 ± 3.204 days in the ward while non-vaccinated patients were admitted for 5.56 ± 4.55 days (p<0.001). ICU stay of the 21 vaccinated patients was a mean length of 4.47 ± 2.3 days while for the 145 non-vaccinated patients was 6.29 ± 2.19 days (p<0.001). Mortality was observed in 4 patients in the vaccinated group and 95 patients in the non-vaccinated group. Conclusion: A single dose of ChAdOx1 nCoV-19 vaccination compared with no vaccination was associated with a significantly lower severity of SARS-CoV-2 infection.

On 11th March 2020, WHO declared COVID-19 a pandemic [World Health Organization, 2020] . Most of the countries have faced massive challenges in combating this disease. As of June, 2021, the cumulative number of cases reported globally has exceeded 180 million and the number of global deaths is almost 4 million across 216 countries.

India has been among the top countries facing sharp surges in identified cases as well as death rate. During the first wave of the pandemic the rate of SARS-CoV-2 infection was somewhat controlled by the nationwide lockdown imposed by the Govt. of India in March 2020 [Singh and Adhikari, 2020] . However, due to increase in the community transmission of the virus, the seven-day average of daily cases in India touched 93,617 on September 16, 2020 which was the highest recorded till then [Pujari and Shekatkar, 2020] .

The global vaccination development efforts by leading pharmaceutical companies have shown positive outcomes in terms of providing immunity and decreasing the severity of the disease with upto 94% efficacy [World Health Organization COVID tracker, 2020] . The Government of India has approved emergency authorization for two of the eight vaccine candidates currently under clinical trials. First is the non-replicating chimpanzee adenovirus vaccine vector ChAdOx1 manufactured by Serum Institute of India in collaboration with University of Oxford and AstraZeneca pharma, under the trade name Covishield TM [Voysey et al, 2021] . The second is the inactivated-virus vaccine BBV152 developed by Bharat Biotech International under the trade name Covaxin TM [Ella et al, 2021a] . In the middle of this crisis India gave restricted approval to the Russian vaccine SPUTNIK-V [ICMR New Delhi, 2021] .

Despite India's large vaccination campaign, only a fraction of the population are vaccinated due to the very large population of the country [Bagcchi, 2021 and Ranjan et al, 2021] . Towards the end of June 2021, 370 million doses have been administered which makes roughly 5% of the total population being fully vaccinated and 22% receiving at least a single dose. Of these, 321.4 million doses of Covishield TM and 45.47 million doses of Covaxin TM have been administered [ICMR New Delhi, 2021] .

On 26 April 2021, India saw the highest daily tally of new SARS-CoV-2 infections ever recorded in the world, 360 960, taking its pandemic total to 16 million cases, second only to the US, and more than 200 000 deaths. The devastating second wave comes a year after the country imposed one of the most rigid lockdown restrictions in the world, and just three months since the health ministry declared that infections and mortality were at an all-time low [Thiagarajan, 2021] .

The second wave of COVID-19 in India has had severe consequences in the form of spiraling cases, reduced supplies of essential treatments, and increased deaths particularly in the young population. Studies have identified various circulating double-mutant and triple mutant strains of the original B.1.617 lineage of SARS-CoV-2, known as Delta AY.1 and Delta AY.2, across different regions of India, which are more pathogenic than the initial strains [Asrani et al, 2021 and Lancet, 2021] . The Delta variant has been reported to be 60% more transmissible than the Alpha variant (B.111.7) and the WHO has designated the Delta variant as a Variant of Concern (VOC) [Kale et al, 2021] .

The government of India has imposed multiple measures to reduce the spread and flatten the curve. The "test-track-treat" protocol has been implemented since April 2021 [Ministry of Home Affairs, 2021] . This includes RT-PCR testing, isolating/quarantining positive cases, tracing of all possible contacts within 72 hours, imposing curfews in major cities, containment zoning in high volume areas, bans on religious/political gatherings, travel restrictions and prioritizing vaccinations for certain population groups.

Getting an infection after vaccination is known as 'breakthrough infection.' 2-4 people per 10,000 breakthrough infections have occurred so far, which is a very small number [Tyagi et al, 2021] . Patients in the first wave infected with SARS-CoV-2 were predominantly older than 60 years and those with comorbid conditions were at increased risk of death. However, surprisingly, younger adults appear to be prone to infection during this second wave and many patients have died at a young age, including patients aged between 25 and 50 years [Jain et al, 2021] .

Our study aims at estimating the real-life impact of a single dose of ChAdOx1 nCoV-19 vaccine on hospitalized patients infected with SARS-CoV-2. Our primary outcome is to determine the efficacy of a single vaccine dose in reducing the severity of SARS-CoV-2 infection. We hope that our results would have some impact in decreasing the vaccine hesitancy in the population and encourage more people to get vaccinated so that maximum immunity can be achieved.

This is a retrospective, single-centre, descriptive observational study based on secondary clinical data analysis of patients admitted to a tertiary COVID care centre (CCC) from 1 st 

Numerical variables are presented as mean ± SD. Discrete variables were summarized by percentages. The qualitative were evaluated using Pearson's chi-square or Fisher's absolute value chi-square test, and Comparison of quantitative variables between two groups will be made by using independent sample t-test or Mann-Whitney test as per normality of data and the results were considered to be statistically significant with a p value of <0.05. The longterm survival for each study group was assessed by Kaplan-Meier analysis with log-rank testing. The results are expressed as hazard ratios (HR) with associated 95% confidence interval. Cox regression analysis was used to determine variables predictive of survival. All analyses were performed in IBM SPSS Statistics, version 26.

This was a retrospective observational study conducted at a single tertiary COVID care center in Western India. Between 1 st April 2021 and 30 th June 2021, 569 patients were enrolled in the study based on the eligibility criteria described previously. There were 347 males and 222 females, with a mean age of 55.55 ± 15.769 years, diagnosed with SARS-CoV-2 infection confirmed by RT-PCR on an oropharyngeal and nasopharyngeal swab. Among the vaccinated patients, mean ± SD age was 61.70 ±15.7 years while that of the non-vaccinated was 53.59±12.1 years and this difference was statistically significant.

One hundred and sixty-nine patients had no chronic comorbidity. On the other hand, 476 patients presented one or more comorbidities as shown in Table 1 . (Diabetes 26.2%, Hypertension 37.6%, IHD 6.5%, Thyroid diseases 4.6%, kidney disease 4.6%, Liver diseases 0.5%, respiratory diseases 2.6% and Neoplasms 1.1%).

Of the 569 patients, 137 (24.08%) had been vaccinated with a single dose of ChAdOx1 nCoV-19 vaccine while 432 (75.92%) had not received any form of vaccination. Table 2 shows the differences between the two groups regarding the length of stay and outcomes during the hospital stay. There was no significant difference in total hospital stay and average length of stay in ward (p value 0.179 and 0.257 respectively). However, there was significant difference in both groups in terms of length of ICU stay (p-value 0.001) and duration of mechanical ventilation (p-value 0.001). 21 vaccinated patients had been admitted in the ICU with a mean stay of 4.47 ± 2.3 days. While 145 patients in the non-vaccinated group were admitted with a mean stay of 6.29 ± 2.19 days [ Figure 1 ]. Similarly, 9 patients in the vaccinated group required mechanical ventilation with a mean of 3.77 ± 2.20 days of support.

While 119 non-vaccinated patients required mechanical ventilation with a mean 6.83 ± 2.28 days of support [ Figure 2 ]. In the non-vaccinated group high rate of mortality was observed 95 (22%) as compared to vaccinated group 4 (2.9%) showing significant results having p value <0.0001. To investigate whether the high difference between groups in age, gender and comorbidity could obscure an association with prognosis in COVID-19 patients, we performed a multinomial logistic regression analysis with mortality as outcome. After correction for gender, age, and comorbidities, we found that vaccination was independently associated with a lower risk of mortality (p < 0.001; HR 0.142; IC 95% 0.051-0.390). This indicates that vaccinated individuals have an additional 86% protection against mortality after a positive covid-19 test result [ Figure 3 ].

Among the total 292 patients with systemic comorbidities, 83 (60.5%) belonged to the vaccinated group and 209 (48.3%) to the non-vaccinated group. There was a significant difference in the ward stay and ICU stay between the two cohorts. Vaccinated patients with comorbidities had a non-significant mean length of stay in the hospital for 8.26±4.57 days and that of non-vaccinated patients was 8.94±7.16 days (p=0.363). But the mean length of stay in the ward was 7.65±4.14 days for the vaccinated patients and 5.09±4.80 days for nonvaccinated patients which was statistically significant (p<0.001). Also, the length of ICU stay was significant (p<0.001) with vaccinated patients staying for a mean 3.61±2.06 days and non-vaccinated patients staying for a mean 6.51±2.64 days.

The COVID-19 pandemic has proven to be the biggest health care challenge of the 21st century especially for a developing country like India. The first wave showed that timely lockdown measures can help in curbing the spread of the disease. However, the second wave from the mutated Delta variant has overwhelmed the medical infrastructure with hospitals struggling to cope with critical drugs and oxygen shortage. As of 30th June 2021, deaths had crossed the 0.4 million mark with 0.11 million in May 2021 alone [COVID-19 Dashboard, 2021] . Prior to April 1 2021, in what can be loosely termed the first COVID-19 wave in India, a little more than 0.16 million deaths had been reported [Worldometers, 2021] .

The priority now is acquiring immunity, which can be either naturally or through vaccines.

Being the second most populous country in the world, it is understandable that the people of India have their perceptions and concerns about COVID-19 vaccines. Distribution of public health information and education about the vaccines had begun before the approval of Covishield TM and Covaxin TM by the government. It is essential that the access and distribution of the vaccines in an equal manner country wide is ensured so that the maximum number of the population is immunized safely and effectively.

WHO has identified vaccine hesitancy as a cause of a global health risk [MacDonald and SAGE group, 2015] . Multiple factors play a role in determining if the newly introduced vaccine will be accepted widely or not. Apart from these, problems of production, manufacturing, marketing, cold-chain maintenance and cost also factor into the advent of new vaccines [Sallam, 2021] .

Normally it would take months to years in order to finish all the phases of a randomized controlled clinical trial to prove the safety and efficacy of a vaccine. However, in the current scenario of rapidly spreading and rapidly mutating virus, it is imperative that accelerated studies and emergency approvals be made effective as soon as possible.

In this study we have tried to reconnoiter the association of partial vaccination with ChAdOx1 nCoV-19 vaccine on various parameters like co-morbidity, ICU requirement, length of stay and mortality in hospitalized COVID-19 patients. Our study has found that the overall hospital stay for vaccinated patients was significantly lower than that for nonvaccinated patients. An ongoing clinical trial showed a single dose of Ad26.COV2.S (Janssen TM ) vaccine gave significant protection against symptomatic and asymptomatic SARS-CoV-2 infected patients and was effective in reducing hospital stay and had lower death rates for severe-critical disease [Sadoff et al, 2021] .

The vaccinated patients in our cohort showed a mean stay of 6.21 days in the ward compared to 5.56 days by the non-vaccinated patients. This shows that a single shot of the vaccine not only makes the patients less vulnerable to severe COVID-19 disease, but also that it can be treated without any need for shifting to intensive care. A similar study among health care professionals by showed improved efficacy of COVID-19 vaccination in terms of hospital stay [Swift et al, 2021] . The overall hospital stay between the groups was similar which could be accounted by the higher mortality in unvaccinated arm resulting in shorter stay compared to the vaccinated group. [Ramakrishnan and Subbarayan, 2021] . Additionally we found that the number of patients with diabetes mellitus and hypertension were more in the vaccinated group, with the hospital stay outcomes being better for that group, indicating that partial vaccination leads to less severity of SARS-CoV-2 infection.

Our study has some limitations. In the absence of non-hospitalized patients, there could have been unmeasured differences between vaccinated and non-vaccinated patients. This study can be extended to include non-hospitalized patients as well. Extended study can be done to include more fully vaccinated patients in the coming months to evaluate the parameters more effectively. Also SARS-CoV-2 antibody levels were tested only in a very small sample of patients due to financial constraints hence was not included in analysis. Various studies have proven higher levels of SARS-CoV-2 antibodies against different antigens in patients who have received a single dose of the vaccine [Jeewandara et al, 2021 and Angyal et al, 2021] . Sample size of our study was also less due to study site limitations. Multicentric study could have been able to provide a huge sample size.

A single dose of ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) is highly effective and has a pivotal role in reducing ICU stay, ventilator usage and mortality even in the peak of COVID-19 pandemic. Safe vaccination is an effective and necessary measure to curb deltavariant or any other COVID-19 variant spread. In countries like India, a complete and early roll out of mass vaccination programs is the key to succeed against COVID-19 pandemic.

Our results are an encouraging signal of the power and promise of vaccines against COVID-19 especially ChAdOx1 nCoV-19. 

T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study

Implications of the second wave of COVID-19 in India. The Lancet. Respiratory Medicine

The world's largest COVID-19 vaccination campaign. The Lancet. Infectious Diseases

COVID-19: Deaths in 2 nd wave cross 2 lakh at daily average of over 2000. The Times of India

COVID-19 vaccine tracker and landscape

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a doubleblind, randomised phase 1 trial. The Lancet Infectious Diseases

Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial

Government of India COVID-19 dashboard

Coronavirus Disease (COVID-19) Dashboard

Recovery or Death) in India -Coronavirus Cases -Worldometer

Differences between first wave and second wave of COVID-19 in India

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers

Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. medRxiv

India's COVID-19 emergency

& SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants

Guidelines for effective control of COVID-19

Multi-city modelling of epidemics using spatial networks: Application to 2019-nCov (COVID-19) coronavirus in India

Impact of vaccination in reducing Hospital expenses, Mortality and Average length of stay among COVID 19 patients. A retrospective cohort study from India. medRxiv

Characterization of the Second Wave of COVID-19 in India. medRxiv

Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19

COVID-19 Vaccine Hesitancy Worldwide-A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel)

Age-structured impact of social distancing on the COVID-19 epidemic in India

Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Why is India having a covid-19 surge?

Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility

Vaccine information, ICMR New Delhi-COVID-19 vaccine

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Weekly epidemiological update on COVID-19 -29

World Health Organization. Director General's opening remarks